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Abstract 
Background: Disturbed nocturnal sleep is a core feature of narcolepsy with cataplexy (NC). 
Several studies have assessed independently sleep disordered breathing (SDB) and periodic 
limb movement disorder (PLMD) in mostly non-homogeneous populations of narcoleptic 
patients.  
The aim of this study was therefore to systematically assess both SDB and PLMD in patients 
with narcolepsy, cataplexy, and hypocretin-1 deficiency.  
Methods: We analyzed clinical and polysomnographic features of 36 consecutive NC patients 
(mean age of 39±16 years, 50% males) in order to assess the prevalence of SDB (AHI>5) and 
of PLMD (PLMI>15) together with their impact on nocturnal sleep and daytime sleepiness at 
the MSLT.  
Results: Eleven (31%) and 14 (39%) patients had SDB and PLMD, respectively. SDB was 
associated with older age (49±5 vs. 35±3 years; p=0.02) and higher BMI (30±1 vs. 26±1 
kg/m2; p=0.04), whereas PLMD with older age (50±4 versus 32±2 years, p=0.001) and sleep 
fragmentation (e.g. sleep efficiency of 82±12% vs 92±6%, p=0.01). SDB and PLMD were 
also mutually associated (p=0.006), but not correlated to daytime sleepiness. 
Conclusions: SDB and PLMD are highly prevalent and associated in NC patients. 
Nevertheless, SDB and PLMD in NC appears to be rarely severe, suggesting an overall 
limited effect on clinical manifestations. 
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Introduction 
Narcolepsy with cataplexy (NC) is characterized by excessive daytime sleepiness (EDS), 
cataplexy, sleep paralysis, and hallucinations. NC is a hypersomnia of central origin, 
pathophysiologically associated with the loss of hypocretin (orexin) producing neurons in the 
hypothalamus [1].  
Besides EDS with daytime naps, NC patients typically suffer from nocturnal sleep 
fragmentation with reduced sleep efficiency, numerous awakenings and larger representation 
of wakefulness after sleep onset and of Non-REM sleep stage 1, resulting in a total sleep time 
per 24 hours which is comparable to controls [2]. Comorbid sleep disordered breathing (SDB) 
[3-5] and periodic limb movement disorder (PLMD) [6-10], both potentially enhancing 
nocturnal sleep disruption, frequently occur in NC patients. Surprisingly, PLMD and SDB 
have not been adequately addressed in the literature: most studies evaluated non-
homogeneous populations of narcoleptic patients with and without cataplexy [7,8,4,11], or 
lacking hypocretin-1 measurements [5,9,10]; others did not synchronously assess movement 
and respiratory disturbances during sleep [3,4,9,10], or applied arbitrary or outdated 
definitions of these sleep disorders [3,4,6-8,11] (Table 1). 
According to the guidelines on narcolepsy treatment of the European Federation of 
Neurological Societies (EFNS) and of the American Academy of Sleep Medicine (AASM) 
[12,13], coexistent sleep disorders must be taken into consideration and treated separately 
along with the specific narcolepsy therapy. Nevertheless, only few studies disclosed a 
negative impact of SDB and PLMD on nocturnal sleep continuity [6,10,11] or, even less, on 
EDS [10,11]. 
The aim of the present study was therefore to investigate the prevalence and the clinical 
relevance of SDB and PLMD in a well-described and homogeneous series of 36 consecutive 
hypocretin-deficient NC patients.  
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Patients and methods 
We analysed sleep data (nocturnal videopolysomnography, VPSG, and multiple sleep latency 
test, MSLT) of 36 consecutive NC patients, referred to the Department of Neurology of the 
University Hospital of Zurich between January 2003 and November 2007. NC was diagnosed 
according to the International Classification of Sleep Disorders, 2nd edition (ICSD-2) [1]. Data 
collection was authorized by the local ethic committee, and patients signed a written informed 
consent. Patients, 50% males, had a mean age of 39±16 years and a mean body mass index 
(BMI) of 28±6 kg/m2. In all patients, clinical examination and cerebral MRI were normal. 
They underwent a VPSG followed by MSLT and completed the Epworth sleepiness scale 
(ESS) for subjective EDS assessment [14]. Thirty-three patients were HLA-DQB1*0602 - 
positive (not available in 1 patient, 1 was DRB1*15 - positive), and 23 out of the 24 
individuals, who underwent lumbar puncture, were hypocretin-1 deficient. Twenty-nine 
subjects were drug-naïve (diagnostic assessment), and 7 subjects were recorded after a wash-
out period of 14 days from stimulant (4 patients), anticataplectic (2 patients) or combined (1 
patient) treatment.  
According to ICSD-2, patients with an apnea-hypopnea index (AHI) ≥ 5/h were considered to 
have SDB, and individuals with an index of periodic leg movements in sleep (PLMI) ≥ 15/h 
to have PLMD [1]. Conforming to AASM criteria, we further differentiated the severity of 
SDB into mild (AHI between 5 and 15/h), moderate (AHI between 15 and 30/h) and severe 
(AHI > 30/h) [15]. Clinical and VPSG features of patients with and without SDB and with 
and without PLMD respectively were compared (Mann-Whitney U test, Pearson Chi Square 
test). A p-value < 0.05 was considered statistically significant. 
 
Results 
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Eleven  patients (31%) were affected by SDB (figure). Mild SDB was diagnosed in 4 (11%) 
subjects, moderate SDB in another 4, and severe SDB in 3 (8%). One of the latter patients 
was a 78-year-old woman with significant cardiovascular comorbidities (arterial hypertension, 
diabetes mellitus type II, and ischemic stroke). In 5 out of 11 (46%) SDB patients, apneas 
were mostly obstructive, whereas in a single subject mostly of central origin. The remaining 5 
patients (46%) showed mixed, obstructive and central apneas. In 2 women with moderate and 
severe obstructive SDB, apneas and hypopneas were mostly associated with REM sleep, 
whereas in the other 9 patients, apnea episodes mainly occurred during NREM sleep stages 1 
and 2. 
NC patients with SDB were significantly older (49±5 vs. 35±3 years; p-value=0.02), had a 
higher BMI (30±1 vs. 26±1 kg/m2; p-value=0.04) and showed a higher PLMI (25±6 vs. 13±4, 
p-value=0.05), especially during light NREM sleep, than subjects without SDB. Additionally, 
SDB patients had a tendency towards larger amounts of NREM sleep stage 1 (21±12% vs. 
15±5%, p=0.086) and less slow wave sleep (SWS) (9±7% vs. 14±6%, p=0.18). We could not 
detect any difference in gender distribution nor in EDS, although SDB was more often 
observed in males than in females (73% vs 40%, p=0.07) (Table 2).  
Fourteen subjects (39%) had PLMD (Figure). We observed PLMs during REM sleep in 9 
subjects, one of them with PLMs selectively during REM sleep (mean PLMI=2). PLMD 
subjects were older than patients without PLMD (50±4 vs. 32±2 years, p= 0.001) without any 
other significant clinical differences. PLMD patients showed lower sleep efficiency (82±12% 
vs. 92±6%, p=0.01), longer REM latency (102±135 vs 17±29 min, p=0.013), less total sleep 
time (353±66 vs. 398±31 min, p=0.007), a larger amount of NREM sleep stage 1 (20±11% vs 
14±5%, p=0.05), a lower amount of NREM sleep stage 2 (36±11% vs 43±6%, p=0.05), and 
less sleep onset REM periods in the MSLT than patients without PLMD (Table 2). 
Finally, SDB was associated with PLMD (p=0.006, Chi square test) (Figure). Despite the 
higher PLMI of patients with SDB, patients with PLMD did not reach statistically significant 
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differences in the respiratory parameters apart from an higher hypopnea index. Neither SDB 
nor PLMD were significantly associated with drug treatment (Table 1). A sub-analysis on the 
23 NC patients with proved hypocretin deficiency yielded analogous results. 
Discussion 
Our study adopted for the first time currently accepted criteria to synchronously assess SDB 
and PLMD in an homogenous population of hypocretin-deficient narcoleptic patients with 
cataplexy free of medication. We obtained the following main findings: 1, SDB and PLMD 
are highly prevalent and mutually associated in NC, especially in older patients; 2, SDB and 
PLMD are rarely severe in NC; and 3, SDB and PLMD enhance nocturnal sleep disruption 
without clinically relevant correlations with daytime symptoms. 
The prevalence of SDB in our NC population (11/36, 31%) is higher than in the general 
population [1], but this is in line with the reported prevalence (33/133, 25% with AHI>10/h) 
in the only study performed in NC patients [5]. The occurrence of SDB in NC patients with 
older age [11,5], and higher BMI [16], not only confirms previous studies in NC, but also 
mirrors the knowledge of SDB risk factors obtained in the general population [1,17]. 
Additionally, our predominantly obstructive (and mixed) SDB argue - together with the 
findings of Sansa et al [5] - against older findings of mainly central apneas [4], and further 
support the comorbidity of NC with mild to moderate nocturnal breathing disturbance [7,8].  
Besides the intrinsic relation between BMI and SDB via upper airway obstruction, other 
pathophysiological mechanisms may contribute to the increased prevalence of SDB in NC. In 
fact, experimental models showed that hypocretin knockout mice have blunted hypercapnic 
ventilatory response during wakefulness with increased sleep apneas [18], and reduced long 
term facilitation after exposure to intermittent hypoxia [19]. Moreover, hypocretin neurons 
are activated by CO2 inhalation [20], and increase pre-inspiratory hypoglossal motor activity 
thus decreasing upper airway resistance during inspiration [21]. 
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Thirty-nine % (14/36) of our NC patients suffer from PLMD, a prevalence significantly 
higher compared to that of the general population and comparable with the two previous 
reports [9,10], further corroborating the evidence of motor control impairment during both 
NREM and REM sleep in NC. In this context, the association between SDB and PLMD is a 
new finding in NC (table 1), with the potential of each sleep related movement or respiratory 
event to induce a shift to a lighter sleep stage where they more frequently occur. Therefore, 
SDB and PLMD mutually interact to disrupt nocturnal sleep continuity and enhance sleep-
wake instability, but the contribution of these two disorders to EDS in NC appears to be 
negligible. Intriguingly, patients without PLMD showed a mildly higher number of sleep 
onset REM periods at the MSLT, a finding potentially linked to a negative correlation 
between sleep onset REM periods and age (Pearson’s correlation coefficient: -0.55, p=0.002), 
as already reported [22].  
We also highlight that only a minority of NC patients have severe SDB or PLMD, which may 
have a true therapeutic implication, thus probably explaining, together with the scarce impact 
on EDS, the commonly found insufficient compliance to CPAP treatment in NC [5,16]. 
Nevertheless, the two disorders should be appropriately treated, especially in severe cases, 
[12,13], in light of their potential contribution to cardiovascular risk [23,24]. Concerning the 
therapy of narcolepsy’s core symptoms, e.g. EDS, only the use of NC-specific medication 
appears to lead to a clinically significant improvement.
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Figure: distribution of sleep disordered breathing (upper part), of periodic limb movement severity (middle part), and association between SDB and 
PLMD (lower part) in the 36 NC patients. 
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Table 1: sleep disordered breathing and periodic leg movements during sleep in different studies of narcoleptic patients 
Study Population SDB AHI>5 AHI>30 PLMD PLMI>5  PLMI>15  Limitations Associations 
Laffont, 1978 18 pts 28% n.a. n.a. n.a. n.a. n.a. 
Absent cut-off for SDB 
definition; 
Unavailable hcrt. n.a. 
Wittig, 1983 57 pts 5% 5% (OAI>25) n.a. 25% n.a. n.a. 
PLMD defined by ≥ 3 
series of 30 PLMs; 
SDB defined by 
OAI>25; unavailable 
hypocretin-1. 
PLMD associated with ↑awakenings, 
↑WASO, ↑NREM1, and older age;  
SDB associated with ↑WASO, 
↑NREM1. 
Mosko, 1984 92 pts 10% 10% (AI>5) n.a. 49% n.a. n.a. 
Patients with and without 
cataplexy; PLMD defined 
by 15% of TST with 
PLMs; unavailable 
hypocretin-1. 
9% of patients with PLMD showed 
SDB 
Baker, 1986 177 pts 13% 13% (AI>5) n.a. 
63% (I); 
46% (II); 
26% (III) n.a. n.a. 
Patients with and without 
cataplexy; PLMD defined 
with different criteria; 
unavailable hypocretin-1. n.a. 
Chokroverty, 
1986 16 pts 69% n.a. n.a. n.a. n.a. n.a. 
Patients with and without 
cataplexy; Daytime PSG; 
Absent cut-off for SDB 
definition¸ unavailable 
hypocretin-1. n.a. 
Harsh, 2000 530 pts 19% 19% n.a. n.a. 46% n.a. 
Patients with and without 
cataplexy; Hypocretin-1 
not reported; PLMD 
defined as PLMI>5; 
unavailable hypocretin-1. 
SDB and PLMD in older patients;  
PLMD associated with ↑arousal 
index, awakenings, NREM1, SWS, 
↓SE, and higher EDS (at MWT);  
SDB with ↑awakenings, ↑NREM1, 
↓SWS and higher EDS (at ESS). 
Sansa, 2009 133 pts 25% 25% (AHI>10) n.a. n.a. n.a. n.a. 
Hypocretin-1 not 
reported; SDB defined as 
AHI>10. 
OSAS associated with male gender, 
↑age and BMI. 
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Ferri, 2006 40 pts n.a. n.a. n.a. 48% 70% 48% 
Hypocretin-1 not 
reported. 
Different periodicity of PLMS 
compared with RLS pts and controls. 
Dauvilliers, 
2007 169 pts n.a. n.a. n.a. 53% 67% n.a. 
Hypocretin-1 not 
reported, PLMD defined 
as PLMI>10. 
PLMD associated with older age, 
↑NREM1, ↓REM, higher EDS 
(MSLT) 
Present Study 36 pts 31% 31% 8% 39% 44% 39%  
SDB associated with older age and 
higher BMI; PLMD associated with 
older age, ↓SE, ↓TST; SDB 
associated with PLMD. 
 
Table Legend:  
SDB, sleep-disordered breathing; PLMD, periodic limb movement disorder; PLMs, periodic limb movements during sleep; OAI, obstructive apnea 
index; WASO, wakefulness after sleep onset; NREM1, Non-REM sleep stage 1; AI, apnea index; TST, total sleep time; I=PLMD defined with at 
least 1 series of ≥ 5 PLMs; II= PLMD defined with al least ≥ 40 PLMs per night; III= PLMD defined with al least ≥ 100 PLMs per night; PSG, 
polysomnoraphy; SWS, slow wave sleep; SE, sleep efficiency; EDS, excessive daytime sleepiness; MWT, maintenance of wakefulness test; ESS, 
Epworth sleepiness scale; BMI, body mass index; RLS, restless legs syndrome; REM, REM sleep; MSLT, multiple sleep latency test.
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Table2: Demographic, polysomnographic and MSLT data of NC patients 
  AHI<5   AHI>5   p-value PLMI<15   PLMI>15   p-value 
  Mean SD Mean SD   Mean SD Mean SD   
Patient Number 25   11     22   14     
Male Sex (%) 40%   73%   ns 41%   64%   ns 
Age 34.9 13.5 49.2 16.5 0.015 32.4 11.1 50.2 16.1 0.001 
Drug treatment (%) 12%  36%  ns 18%  29%  ns 
BMI 26.5 6.0 30.4 4.8 0.038 27.8 6.9 27.6 3.9 ns 
ESS 16 3.8 15.6 4.4 ns 15.0 3.3 17.2 4.6 ns 
TST (min) 384.1 52.9 371.9 52.1 ns 398.1 31.1 352.6 66.5 0.007 
SE (%) 88.6 10.4 86.3 8.9 ns 91.7 5.7 82.1 12.4 0.01 
SL  (min) 13.7 12.9 10.9 21.3 ns 13.4 12.4 11.9 20.4 ns 
REM L (min) 26.2 44.6 103.2 149.8 ns 16.7 28.6 101.6 135.5 0.013 
NREM1 (%) 14.9 5.4 21.3 11.7 ns 14.5 5.5 20.5 10.6 0.05 
NREM2 (%) 41.6 8.4 38.4 10.5 ns 43.4 6.4 36.2 10.9 0.05 
NREM3 (%) 13.8 6.4 9.5 6.8 ns 14.4 5.8 9.5 7.1 ns 
REM (%) 18.5 7.2 17.1 11.1 ns 19.4 7.3 15.9 9.9 ns 
Central AI 0.2 0.4 3.1 5.4 0.013 1.3 4.1 0.6 0.9 ns 
Mixed AI 0.1 0.1 2.4 3.6 <0.0001 0.7 2.4 0.9 1.9 ns 
Obstructive AI 0.2 0.4 5.9 5.8 <0.0001 1.1 2.4 3.2 5.8 ns 
Hypopnea Index 0.8 0.9 10.3 7.1 <0.0001 2.2 3.8 6.0 7.7 0.036 
AHI 1.2 1.3 21.7 14.4 <0.0001 5.4 11.2 10.8 13.7 ns 
Arousal Index 10.3 5.1 11.9 8.2 ns 10.5 5.9 11.4 6.7 ns 
PLMI 12.7 22.7 25.4 19.8 0.046 1.2 2.6 40.7 17.7 <0.0001 
PLMI in NREM1 9.5 21.6 22.1 17.5 0.011 1.1 3.1 33.3 23.3 <0.0001 
PLMI in NREM2 17.8 30.8 30.8 30.5 0.049 1.9 4.3 54.8 27.4 <0.0001 
PLMI in NREM3 28.1 60.4 73.6 100.5 ns 1.4 5.6 108.1 91.2 <0.0001 
PLMI in REM 1.2 2.5 6.8 10.3 ns 0.3 1.6 6.8 8.8 <0.0005 
MSLT SL (min) 2.1 1.5 1.8 1.3 ns 2.0 1.6 1.9 1.3 ns 
MSLT REM L (min) 3.8 2.3 5.4 3.7 ns 3.8 2.1 5.2 3. 7 ns 
SOREMPs  3.4 0.8 3.3 1.0 ns 3.6 0.6 2.9 1.1 0.043 
 
Table legend: 
BMI = body mass index, ESS = Epworth Sleepiness Scale, TST = total sleep time, SE = sleep 
efficiency, SL = sleep latency, REM L = REM latency, NREM= non-REM sleep stage, AI = 
apnea index, AHI = apnea hypopnea index, SpO2= peripheral oxygen saturation, PLMI = 
periodic limb movement index, SOREMPs= Sleep onset REM periods. 
